Linezolid (Zyvox)

An oxazolidinone and acetamide derived ANTI-BACTERIAL AGENT and PROTEIN SYNTHESIS INHIBITOR that is used in the treatment of GRAM-POSITIVE BACTERIAL INFECTIONS of the skin and respiratory tract.

Also Known As:

Networked: 2842 relevant articles (390 outcomes, 512 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Tsuji, Yasuhiro: 18 articles (04/2021 - 04/2008)
2.	Peloquin, Charles A: 15 articles (09/2022 - 08/2003)
3.	Jones, Ronald N: 15 articles (04/2014 - 07/2005)
4.	Falagas, Matthew E: 13 articles (04/2015 - 08/2006)
5.	De Anda, Carisa: 12 articles (09/2022 - 02/2013)
6.	Hsueh, Po-Ren: 12 articles (04/2022 - 04/2004)
7.	Yamamoto, Yoshihiro: 12 articles (04/2021 - 11/2009)
8.	Alffenaar, Jan-Willem C: 12 articles (01/2020 - 02/2010)
9.	Grau, Santiago: 12 articles (12/2019 - 08/2005)
10.	Rybak, Michael J: 12 articles (01/2019 - 08/2002)

Related Diseases

1.	Infections 08/01/2001 - "The preclinical promise of linezolid was realized in human clinical trials where linezolid was highly efficacious in the treatment of medically significant Gram-positive infections." 01/01/2023 - "Linezolid appeared to be the most promising treatment regimen for staphylococcal bone and joint infections. " 06/01/2012 - "All cases exhibited long-term tolerance of linezolid, and 14 of 15 cases showed either an improvement in or complete clearance of the infection. " 12/01/2021 - "Phage MR-5 alone and in combination with linezolid (showing synergy) brought significant reduction in the bacterial load (both extracellular as well as intracellular) that led to faster resolution of pouch infection. " 01/01/2018 - "The exosomal formulation of linezolid was more effective against intracellular MRSA infections in vitro and in vivo than the free linezolid. "
2.	Pneumonia (Pneumonitis) 01/01/2019 - "Mesenchymal stem cells significantly improved treatment effects of Linezolid on severe pneumonia in a rabbit model." 06/01/2011 - "After the change from VCM to linezolid (LZD), the VAP improved promptly, indicating that LZD is superior to VCM in the treatment of MRSA pneumonia." 12/01/2010 - "Combined retrospective analysis of seven phase II and III trials of the efficacy of linezolid in the treatment of pneumonia caused by multidrug-resistant Streptococcus pneumoniae." 01/01/2019 - "The main goal of this study was to evaluate PK/pharmacodynamic (PKPD) target attainment when using a 600 mg intravenous q12h linezolid dose against MRSA in obese patients with pneumonia. " 10/01/2012 - "Results of the ZEPHyR trial do not support routine use of linezolid for the treatment of MRSA pneumonia."
3.	Endocarditis 08/01/2008 - "Orally administered linezolid is effective in limiting bacterial growth in the secondary foci of endocarditis. " 08/01/2006 - "We carried out a review of the available literature to evaluate whether linezolid is also effective for the treatment of patients with infective endocarditis. " 02/15/2004 - "Eighteen patients received linezolid, which was effective in 14 (78%), including 4 patients with endocarditis. " 02/01/2006 - "There are no experimental studies regarding the prophylactic efficacy of linezolid against infective endocarditis. " 12/23/2021 - "Current data on the frequency and efficacy of linezolid (LNZ) in infective endocarditis (IE) are based on small retrospective series. "
4.	Healthcare-Associated Pneumonia 09/01/2014 - "In summary, linezolid may be a cost-effective treatment strategy in MRSA-confirmed nosocomial pneumonia." 02/01/2001 - "Linezolid is a well-tolerated, effective treatment for adults with gram-positive nosocomial pneumonia." 12/01/2010 - "Data from 7 Phase II and III clinical trials that assessed the efficacy of linezolid in community- or hospital-acquired pneumonia were pooled. " 04/05/2003 - "Three clinical trials in patients with nosocomial pneumonia assessed the efficacy of linezolid. " 01/01/2016 - "In summary, results from both clinical and economic studies, including studies conducted from a Chinese perspective, support the use of linezolid for the treatment of patients with MRSA nosocomial pneumonia. "
5.	Bacteremia 04/11/2017 - "Objective: To study the efficacy and safety of linezolid for the treatment of patients with bacteremia caused by methicillin-resistant Staphylococcus aureus (MRSA). " 09/01/2023 - "Genomic Analysis of a Linezolid-Resistant Staphylococcus capitis Causing Bacteremia: Report from a University Hospital in Central Italy." 01/01/2019 - "In vitro phenotypes of cfr-positive MRSA translated into poor outcomes of linezolid monotherapy in vivo in murine bacteremia and SSSI models. " 10/01/2018 - "VRE bacteremia recurred after discontinuation of linezolid; therefore, linezolid was re-prescribed at the lower dose (600 mg). " 10/01/2018 - "VRE bacteremia quickly resolved following linezolid treatment, and vasopressor use was reduced. "

Related Drugs and Biologics

1.	Vancomycin
2.	Anti-Bacterial Agents (Antibiotics)
3.	Oxazolidinones (2 Oxazolidone)
4.	Daptomycin
5.	Rifampin (Rifampicin)
6.	Glycopeptides
7.	bedaquiline (R207910)
8.	Tigecycline (Tygacil)
9.	tedizolid
10.	pretomanid

Related Therapies and Procedures

1.	Therapeutics
2.	Duration of Therapy
3.	Salvage Therapy
4.	Debridement
5.	Catheters